The Positive Papers

1. India's clean-energy push hits a milestone: Coal power sees no growth for first time in 50 years
   India's electricity generation from coal remained flat for the first time in half a century while overall power demand rose. The milestone reflects faster deployment of solar, wind, and other renewables that now cover the incremental load. The shift reduces the country's annual emissions growth trajectory without requiring immediate plant retirements. Grid operators still face the practical challenge of balancing variable renewable output with existing coal plants that provide baseload stability. Early data suggest the trend can continue if storage and transmission keep pace, yet the exact pace depends on state-level project execution. The open question is whether this marks a permanent plateau or a temporary pause driven by one year's project pipeline. The data point arrives from reporting dated September 17, 2026. Renewables are absorbing new demand that would otherwise have required additional coal capacity. This pattern holds even as total electricity consumption continues its upward climb. Builders in the renewable sector can point to measurable displacement of new fossil capacity without waiting for full plant retirements. Source: moneycontrol.com
2. New mesothelioma drug turns cancer’s own defenses against it
   An experimental drug disables the PRX3 antioxidant protein that mesothelioma tumors rely on to survive oxidative stress. In an early clinical trial the compound controlled disease progression in 67 percent of patients and produced encouraging survival signals. The approach is counterintuitive because it attacks a defense mechanism rather than the cancer cells directly. The trial remains small and early-stage, so larger studies are needed to confirm durability and safety across broader populations. If the mechanism holds, similar strategies could apply to other oxidative-stress-dependent cancers. The open question is how quickly this moves from trial to approved therapy and which patients benefit most. The compound was tested in patients with an aggressive asbestos-linked cancer that has few effective treatments. Disease control at the 67 percent mark came with survival results described as encouraging by the reporting team. The strategy exploits the intense oxidative stress already present inside these tumors. Translation to routine care will require confirmation that the effect persists beyond the initial cohort. Source: sciencedaily.com
3. Hidden “immune organ” in the skull may help fight brain cancer
   Strengthening this local response improved tumor rejection and extended survival. The finding points to a previously overlooked pathway that bypasses the blood-brain barrier. Results are still limited to preclinical models, and translation to humans will require safety and delivery studies. If the pathway proves actionable, new treatments could target the skull directly rather than relying solely on systemic drugs. The open question is whether this immune niche can be modulated in patients without unintended effects on other brain functions. The discovery shows the skull contains an immune population capable of quick mobilization against intracranial tumors. In the mouse experiments, enhancing that local defense produced measurable gains in tumor rejection. The mechanism offers a route around the protective barrier that normally limits drug access to the brain. Human application will first need verification that skull-targeted interventions remain safe and specific. Source: sciencedaily.com

Think Positive

Martin Seligman’s work on learned optimism shows that people can train themselves to treat setbacks as temporary and specific rather than permanent and pervasive. This shift in explanatory style reduces helplessness and improves persistence on difficult tasks. When builders face slow regulatory approvals or uncertain trial results, the same habit keeps effort moving forward instead of stalling. One concrete mental rep today is to write one sentence reframing a current obstacle as “this is one variable that can be tested,” then take the smallest next action on it. The practice draws directly from decades of research on how explanatory style influences resilience. It pairs naturally with the incremental milestones seen in both energy deployment and early-stage medical trials. A single reframing step lowers the emotional cost of continuing when outcomes remain uncertain. Over repeated days the habit compounds into greater willingness to ship imperfect work.

The Lever

Open ClinicalTrials.gov today, search for “mesothelioma PRX3” or “PRX3 inhibitor,” filter for recruiting studies, and note the contact information for the single most relevant open trial. The step takes roughly ten to fifteen minutes on a computer or phone. If a trial matches a patient you know, the next action is one email or phone call to the listed coordinator. Early trial participation can accelerate data collection that moves promising compounds toward approval. At honest scale, if even one in a thousand listeners performs the search and one in ten of those finds a match, dozens of additional screened patients could reach trials each month. The main barrier is not knowing the exact search terms; the fix is to copy the two phrases above and paste them directly into the site. The action ends with a saved note containing a real coordinator’s email or phone number. No special credentials are required to begin the search. The same platform already lists thousands of recruiting studies across cancer types. One person’s ten-minute effort can surface an option that would otherwise remain unseen by that household. Source the impact numbers where the articles provide them: https://www.sciencedaily.com/releases/2026/09/260915232136.htm

Do Positive Dispatch

Yesterday’s lever was to contact your regional wildlife authority this week and ask to join an existing species-monitoring volunteer roster; send a short note with the one result you got from that call.

Network pick: First Principles Daily (today): “Electric arc furnaces let one engineer melt scrap into specialty steel in hours instead of…”

Sources

https://www.moneycontrol.com/news/business/india-s-clean-energy-push-hits-a-milestone-coal-power-sees-no-growth-for-first-time-in-50-years-14031996.html https://www.sciencedaily.com/releases/2026/09/260915232136.htm https://www.sciencedaily.com/releases/2026/09/260915232134.htm

Do something about it.

💬 Reply to this email — Patrick reads every one.

Share: X · LinkedIn · WhatsApp

Forwarded this email? Subscribe here — it's free.